Review



zanidatamab crossmab  (Zymeworks)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Zymeworks zanidatamab crossmab
    Current clinical trials of bsAbs based on mechanism of action in solid malignancies.
    Zanidatamab Crossmab, supplied by Zymeworks, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zanidatamab+crossmab/zanidatamab/pmc09694302-18-2-16
    Average 90 stars, based on 1 article reviews
    zanidatamab crossmab - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors"

    Article Title: Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

    Journal: Pharmaceutics

    doi: 10.3390/pharmaceutics14112442

    Current clinical trials of bsAbs based on mechanism of action in solid malignancies.
    Figure Legend Snippet: Current clinical trials of bsAbs based on mechanism of action in solid malignancies.

    Techniques Used: Clinical Proteomics

    Related Articles

    Clinical Proteomics:

    Article Title: Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
    Article Snippet: Zanidatamab , CrossMab , HER2 , Solid tumors , 1 , NCT02892123 , ANR , , Zymeworks Inc./BeiGene, Ltd. (Vancouver, BC, Canada).



    Similar Products

    zanidatamab crossmab  (Zymeworks)
    90
    Zymeworks zanidatamab crossmab
    Current clinical trials of bsAbs based on mechanism of action in solid malignancies.
    Zanidatamab Crossmab, supplied by Zymeworks, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/zanidatamab+crossmab/zanidatamab/pmc09694302-18-2-16
    Average 90 stars, based on 1 article reviews
    zanidatamab crossmab - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Current clinical trials of bsAbs based on mechanism of action in solid malignancies.

    Journal: Pharmaceutics

    Article Title: Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

    doi: 10.3390/pharmaceutics14112442

    Figure Lengend Snippet: Current clinical trials of bsAbs based on mechanism of action in solid malignancies.

    Article Snippet: Zanidatamab , CrossMab , HER2 , Solid tumors , 1 , NCT02892123 , ANR , , Zymeworks Inc./BeiGene, Ltd. (Vancouver, BC, Canada).

    Techniques: Clinical Proteomics